1. 1320 Eribulin mesylate in metastatic breast cancer, a focus on safety and efficacy in elderly patients. Results from the EVHALAVEN multicentric retrospective cohort. (September 2015) Authors: Martin-babau, J.; Robert, M.; Septans, A.L.; Paillard, M.J.; Pivot, X.; Soibinet, P.; Gourmelon, C.; Brunot, A.; Lefeuvre-plesse, C.; Korenbaum, C.; Petit, T.; Marquis, A.; Bourgeois, H.; Uwer, L.; Som, M.; Desclos, H.; Campone, M.; Campion, L.; Tredan, O.; Patsouris, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1865 Activity and toxicity profile of eribulin mesylate in heavily pretreated metastatic breast cancer: An observational study (EVHALAVEN). (September 2015) Authors: Patsouris, A.; Septans, A.L.; Paillard, M.J.; Pivot, X.; Soibinet, P.; Jovenin, N.; Robert, M.; Gourmelon, C.; Korembaum, C.; Petit, T.; Martin-babau, J.; Brunot, A.; Lefeuvre-plesse, C.; Adele, M.; Bourgeois, H.; Som, M.; Uwer, L.; Campone, M.; Campion, L.; Tredan, O. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S287 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 209 The sum of gains and losses of genes encoding for protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment. (September 2015) Authors: Jiang, X.; Pissaloux, D.; De La Fouchardiere, C.; Desseigne, F.; Wang, Q.; Fondrevelle, M.E.; Cassier, P.; Seigne, C.; Perol, D.; Ray-Coquard, I.; Le Cesne, A.; Penel, N.; Tredan, O.; Blay, J.Y. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 31LBA MOST – My Own Specific Therapy – A multicenter, randomized, open-label, phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors: preliminary results from the everolimus and sorafenib cohorts. (September 2015) Authors: Toulmonde, M.; Le Tourneau, C.; Cropet, C.; Italiano, A.; Bertucci, F.; Ray-Coquard, I.; Tredan, O.; Cassier, P.; Seigne, C.; De la Fouchardiere, C.; Flechon, A.; Desseigne, F.; Frappaz, D.; Gomez-Roca, C.A.; Heudel, P.E.; You, B.; Jaouen, L.; Bernardin, M.; Perol, D.; Blay, J.Y. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S725 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay. (3rd March 2016) Authors: Verronèse, E.; Delgado, A.; Valladeau-Guilemond, J.; Garin, G.; Guillemaut, S.; Tredan, O.; Ray-Coquard, I.; Bachelot, T.; N'Kodia, A.; Bardin-Dit-Courageot, C.; Rigal, C.; Pérol, D.; Caux, C.; Ménétrier-Caux, C. Journal: Oncoimmunology Issue: Volume 5:Number 3(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗